MDGL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$237.00 |
| 52 Week High | US$299.98 |
| 52 Week Low | US$119.76 |
| Beta | -0.43 |
| 11 Month Change | -16.66% |
| 3 Month Change | 15.47% |
| 1 Year Change | 38.25% |
| 33 Year Change | 179.28% |
| 5 Year Change | 156.30% |
| Change since IPO | 2,234.95% |
Recent News & Updates
Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09
While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Recent updates
Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28
Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Shareholder Returns
| MDGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.9% | -2.2% | -2.3% |
| 1Y | 38.2% | 13.9% | 16.7% |
Return vs Industry: MDGL exceeded the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: MDGL exceeded the US Market which returned 16.7% over the past year.
Price Volatility
| MDGL volatility | |
|---|---|
| MDGL Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MDGL has not had significant price volatility in the past 3 months.
Volatility Over Time: MDGL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| MDGL fundamental statistics | |
|---|---|
| Market cap | US$5.29b |
| Earnings (TTM) | -US$510.45m |
| Revenue (TTM) | US$14.64m |
351.5x
P/S Ratio-10.1x
P/E RatioIs MDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGL income statement (TTM) | |
|---|---|
| Revenue | US$14.64m |
| Cost of Revenue | US$636.00k |
| Gross Profit | US$14.00m |
| Other Expenses | US$524.45m |
| Earnings | -US$510.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.51 |
| Gross Margin | 95.66% |
| Net Profit Margin | -3,487.13% |
| Debt/Equity Ratio | 13.6% |
How did MDGL perform over the long term?
See historical performance and comparison